NO972930L - Fibronectin-adhesjonsinhibitorer - Google Patents

Fibronectin-adhesjonsinhibitorer

Info

Publication number
NO972930L
NO972930L NO972930A NO972930A NO972930L NO 972930 L NO972930 L NO 972930L NO 972930 A NO972930 A NO 972930A NO 972930 A NO972930 A NO 972930A NO 972930 L NO972930 L NO 972930L
Authority
NO
Norway
Prior art keywords
amino acid
acid selected
fibronectin
terminus
linker
Prior art date
Application number
NO972930A
Other languages
English (en)
Other versions
NO972930D0 (no
Inventor
Anand Swaroop Dutta
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9426254.0A external-priority patent/GB9426254D0/en
Priority claimed from GBGB9505905.1A external-priority patent/GB9505905D0/en
Priority claimed from GBGB9513904.4A external-priority patent/GB9513904D0/en
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Publication of NO972930D0 publication Critical patent/NO972930D0/no
Publication of NO972930L publication Critical patent/NO972930L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Det beskrives cykliske peptider med formel (1) >-.AA1-AA2-AA3-AA'^ LINKER' (1) hvor AA1 er en L- eller ^-aminosyre valgt fra Ile ogLeu eller en aminosyreanalog derav, AA2 er en L-aminosyre valgl fra Lau eller en aminosyreanalog derav, AA3 er en L-aminosyre valgt fra Asp eller en aminosyreanalog cderav, som i sin sidekjede inneholderen karboksylgruppe; AA4 er en L-aminosyre valgt fra Val eller en aminosyreanalog derav, og; LINKER representerer en sammenkoblende del for å koble N-enden av AA1 til C- enden av AA4 under dannelse av et cyklisk peptid som inneholder en heterocyklisk ring som har 17 til 30 ledd. De cykliske peptidene inhiberer interaksjonen mellom VCAM-1 (Vascular Cell Adhesion Molecule-1) og fibronectin, med integrinet VLA-4 (Very Late Antigen 4) og har terapeutiske anvendelser, f eks. ved reumatoid artritt eller multippel sklerose.
NO972930A 1994-12-24 1997-06-23 Fibronectin-adhesjonsinhibitorer NO972930L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9426254.0A GB9426254D0 (en) 1994-12-24 1994-12-24 Chemical compounds
GBGB9505905.1A GB9505905D0 (en) 1995-03-23 1995-03-23 Methods
GBGB9513904.4A GB9513904D0 (en) 1995-07-07 1995-07-07 Chemical compounds
PCT/GB1995/002992 WO1996020216A1 (en) 1994-12-24 1995-12-21 Fibronectin adhesion inhibitors

Publications (2)

Publication Number Publication Date
NO972930D0 NO972930D0 (no) 1997-06-23
NO972930L true NO972930L (no) 1997-08-19

Family

ID=27267539

Family Applications (1)

Application Number Title Priority Date Filing Date
NO972930A NO972930L (no) 1994-12-24 1997-06-23 Fibronectin-adhesjonsinhibitorer

Country Status (18)

Country Link
US (1) US6034056A (no)
EP (1) EP0800535A1 (no)
JP (1) JP3248584B2 (no)
CN (1) CN1171118A (no)
AU (1) AU705717B2 (no)
BR (1) BR9510284A (no)
CA (1) CA2204793A1 (no)
CZ (1) CZ198497A3 (no)
GB (1) GB9524630D0 (no)
HU (1) HUT77120A (no)
IL (1) IL116512A0 (no)
MX (1) MX9704767A (no)
NO (1) NO972930L (no)
NZ (1) NZ297530A (no)
PL (1) PL320995A1 (no)
SK (1) SK81097A3 (no)
TR (1) TR199501656A2 (no)
WO (1) WO1996020216A1 (no)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11508583A (ja) * 1995-07-06 1999-07-27 ゼネカ・リミテッド ペプチド系のフィブロネクチン阻害薬
GB9613112D0 (en) 1996-06-21 1996-08-28 Zeneca Ltd Chemical compounds
DE19647382A1 (de) 1996-11-15 1998-05-20 Hoechst Ag Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
DE19647381A1 (de) 1996-11-15 1998-05-20 Hoechst Ag Neue Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
DE19653036A1 (de) * 1996-12-19 1998-06-25 Merck Patent Gmbh Cyclopeptidderivate
US6221888B1 (en) 1997-05-29 2001-04-24 Merck & Co., Inc. Sulfonamides as cell adhesion inhibitors
US6291511B1 (en) 1997-05-29 2001-09-18 Merck & Co., Inc. Biarylalkanoic acids as cell adhesion inhibitors
US6903075B1 (en) 1997-05-29 2005-06-07 Merck & Co., Inc. Heterocyclic amide compounds as cell adhesion inhibitors
DE19741235A1 (de) 1997-09-18 1999-03-25 Hoechst Marion Roussel De Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19741873A1 (de) * 1997-09-23 1999-03-25 Hoechst Marion Roussel De Gmbh Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
US6069163A (en) * 1997-10-21 2000-05-30 Merck & Co., Inc. Azapeptide acids as cell adhesion inhibitors
US6020347A (en) * 1997-11-18 2000-02-01 Merck & Co., Inc. 4-substituted-4-piperidine carboxamide derivatives
DE19751251A1 (de) 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
US6191171B1 (en) 1997-11-20 2001-02-20 Merck & Co., Inc. Para-aminomethylaryl carboxamide derivatives
US6090841A (en) * 1997-11-21 2000-07-18 Merck & Co., Inc. Substituted pyrrole derivatives as cell adhesion inhibitors
US6645939B1 (en) 1997-11-24 2003-11-11 Merck & Co., Inc. Substituted β-alanine derivatives as cell adhesion inhibitors
DE19821483A1 (de) 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19922462A1 (de) 1999-05-17 2000-11-23 Aventis Pharma Gmbh Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate
AU783110B2 (en) 1999-12-16 2005-09-22 Biogen Ma Inc. Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists
YU41202A (sh) 1999-12-28 2005-03-15 Pfizer Products Inc. Ne-peptidni inhibitori vezivanja za ćeliju zavisnog od vla-4 korisni pri tretiranju inflamatornih, autoimunih i respiratornih bolesti
GB0015923D0 (en) * 2000-06-30 2000-08-23 Astrazeneca Ab Methods
DE10111877A1 (de) 2001-03-10 2002-09-12 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
PT1423400E (pt) * 2001-03-19 2006-12-29 Harvard College Evolução de nova função molecular
DE10137595A1 (de) 2001-08-01 2003-02-13 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung
WO2003019136A2 (en) * 2001-08-06 2003-03-06 The Regents Of The University Of California Methods for inhibiting angiogenesis
AR038136A1 (es) 2002-01-24 2004-12-29 Merck Frosst Canada Inc Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
AU2003284984B2 (en) 2002-10-30 2008-10-23 Merck Sharp & Dohme Corp. Gamma-aminoamide modulators of chemokine receptor activity
AU2004278748B2 (en) 2003-09-29 2008-09-11 The Regents Of The University Of California Methods for altering hematopoietic progenitor cell adhesion, differentiation, and migration
SE0302853D0 (sv) * 2003-10-29 2003-10-29 Astrazeneca Ab Chemical compounds
ES2431524T3 (es) 2004-04-13 2013-11-26 Incyte Corporation Derivados de piperazinilpiperidina como antagonistas de los receptores de quimiocinas
MEP1008A (xx) 2005-12-21 2010-02-10 Incyte Corp 3-aminociklopentankarboksamidi kao modulatori receptora hemokina
US8808698B2 (en) 2006-02-03 2014-08-19 The Regents Of The University Of California Methods for inhibition of lymphangiogenesis and tumor metastasis
AU2008219007A1 (en) 2007-02-20 2008-08-28 Merrimack Pharmaceuticals, Inc. Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
FR2914304B1 (fr) * 2007-03-28 2012-11-16 Guerbet Sa Composes pour le diagnostic de maladies liees a l'expression de vcam.
WO2010031183A1 (en) 2008-09-22 2010-03-25 Merck Frosst Canada Ltd. Indole derivatives as crth2 receptor antagonists
MX2011004550A (es) * 2008-10-31 2011-07-20 Centocor Ortho Biotech Inc Composiciones de de supercóntigos a base de dominios de fibronectina tipo iii, métodos y usos.
WO2010053572A2 (en) 2008-11-07 2010-05-14 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
PL2370442T3 (pl) 2008-11-26 2013-08-30 Pfizer 3-Aminocyklopentanokarboksamidy jako modulatory receptora chemokiny
SG172857A1 (en) 2009-02-09 2011-08-29 Supergen Inc Pyrrolopyrimidinyl axl kinase inhibitors
MA33134B1 (fr) 2009-02-24 2012-03-01 Merck Canada Inc Derives d'indole en tant qu'antagonistes du recepteur crth2
EP2467159A1 (en) 2009-08-20 2012-06-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy
EP2547693B1 (en) 2010-03-19 2015-03-11 H. Lee Moffitt Cancer Center & Research Institute Integrin interaction inhibitors for the treatment of cancer
US8927559B2 (en) 2010-10-11 2015-01-06 Merck Sharp & Dohme Corp. Quinazolinone-type compounds as CRTH2 antagonists
BR112013015397A2 (pt) 2010-12-23 2016-09-20 Merck Sharp & Dohme composto, composição farmacêutica, e, uso de um composto
US9428845B1 (en) 2010-12-28 2016-08-30 Warp Drive Bio, Inc. Identifying new therapeutic agents
CA2831392C (en) 2011-03-28 2020-04-28 Massachusetts Institute Of Technology Conjugated lipomers and uses thereof
WO2012151137A1 (en) 2011-05-04 2012-11-08 Merck Sharp & Dohme Corp. Amino-pyridine-containing spleen tyrosine kinase (syk) inhibitors
PH12013502619A1 (en) 2011-06-17 2014-02-17 Merck Sharp & Dohme Cycloalkyl-fused tetrahydroquinolines as crth2 receptor modulators
US8987456B2 (en) 2011-10-05 2015-03-24 Merck Sharp & Dohme Corp. 3-pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors
US9512073B2 (en) 2011-10-27 2016-12-06 Massachusetts Institute Of Technology Amino acid-, peptide-and polypeptide-lipids, isomers, compositions, and uses thereof
WO2014028487A1 (en) 2012-08-13 2014-02-20 Massachusetts Institute Of Technology Amine-containing lipidoids and uses thereof
WO2015048477A1 (en) 2013-09-27 2015-04-02 H. Lee Moffitt Cancer Center And Research Institute, Inc. Cyclic peptide conjugates and methods of use
GB201400292D0 (en) * 2014-01-08 2014-02-26 Haemostatix Ltd Peptide dendrimers and agents
WO2015184256A2 (en) 2014-05-30 2015-12-03 Shire Human Genetic Therapies, Inc. Biodegradable lipids for delivery of nucleic acids
KR102559979B1 (ko) 2014-06-24 2023-07-25 샤이어 휴먼 지네틱 테라피즈 인크. 핵산의 전달용 입체화학적으로 풍부한 조성물
WO2016004202A1 (en) 2014-07-02 2016-01-07 Massachusetts Institute Of Technology Polyamine-fatty acid derived lipidoids and uses thereof
WO2016112295A1 (en) 2015-01-09 2016-07-14 Warp Drive Bio, Inc. Compounds that participate in cooperative binding and uses thereof
TW201629069A (zh) 2015-01-09 2016-08-16 霍普驅動生物科技股份有限公司 參與協同結合之化合物及其用途
RS64331B1 (sr) 2015-06-19 2023-08-31 Massachusetts Inst Technology Alkenil supstituisani 2,5-piperazindioni i njihova primena u sastavima za isporuku agensa u organizam ili ćeliju subjekta
CA3000822A1 (en) 2015-10-01 2017-04-06 Warp Drive Bio, Inc. Methods and reagents for analyzing protein-protein interfaces
EP3377471A4 (en) 2015-11-11 2019-11-20 Encycle Therapeutics, Inc. FRAGMENT SYNTHESIS OF CYCLIC PEPTIDES
CA3020594A1 (en) 2016-04-12 2017-10-19 Warp Drive Bio, Inc. Compositions and methods for the production of compounds
CN110506120A (zh) 2016-10-28 2019-11-26 银杏生物制品公司 用于生产化合物的组合物和方法
EP3939989A1 (en) * 2016-11-11 2022-01-19 Zealand Pharma A/S Cyclic peptides multimers targeting alpha 4beta 7 integrin
WO2018140510A1 (en) 2017-01-25 2018-08-02 Biogen Ma Inc. Compositions and methods for treatment of stroke and other cns disorders
KR20200015540A (ko) * 2017-05-10 2020-02-12 인사이클 세라퓨틱스, 인코포레이티드 α4β7 인테그린을 타겟팅하는 호모데틱 사이클릭 펩타이드
WO2020143793A1 (zh) 2019-01-10 2020-07-16 石药集团中奇制药技术（石家庄）有限公司 杂环化合物盐及其应用
MX2022005359A (es) 2019-11-04 2022-06-02 Revolution Medicines Inc Inhibidores de ras.
CN121471132A (zh) 2019-11-04 2026-02-06 锐新医药公司 Ras抑制剂
WO2021091956A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
IL301298A (en) 2020-09-15 2023-05-01 Revolution Medicines Inc Indole derivatives as RAS inhibitors in cancer therapy
US20240301512A1 (en) 2021-01-29 2024-09-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of assessing the risk of developing progressive multifocal leukoencephalopathy in patients treated with vla-4 antagonists
IL308195A (en) 2021-05-05 2024-01-01 Revolution Medicines Inc RAS inhibitors for cancer treatment
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZW6189A1 (en) * 1988-05-09 1990-05-09 Smithkline Beckman Corp Anti-aggregatory peptides
NZ235563A (en) * 1989-10-13 1993-04-28 Merck & Co Inc Fibrinogen receptor antagonist and pharmaceutical composition
US5192746A (en) * 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds
IL102646A (en) * 1992-07-26 1996-05-14 Yeda Res & Dev Non-peptidic surrogates of the ldv sequence and pharmaceutical compositions comprising them
EP0677060A1 (en) * 1993-01-08 1995-10-18 Tanabe Seiyaku Co., Ltd. Peptide inhibitors of cell adhesion
US5981478A (en) * 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides
AU2958195A (en) * 1994-06-29 1996-01-25 Texas Biotechnology Corporation Process to inhibit binding of the integrin alpha 4 beta 1 to vcam-1 or fibronectin
US5811391A (en) * 1994-08-25 1998-09-22 Cytel Corporation Cyclic CS-1 peptidomimetics, compositions and methods of using same
JPH09507988A (ja) * 1994-11-02 1997-08-12 フィリップス エレクトロニクス ネムローゼ フェンノートシャップ 波形発生

Also Published As

Publication number Publication date
HUT77120A (hu) 1998-03-02
CN1171118A (zh) 1998-01-21
EP0800535A1 (en) 1997-10-15
JPH10508315A (ja) 1998-08-18
CA2204793A1 (en) 1996-07-04
MX9704767A (es) 1997-10-31
NZ297530A (en) 2000-02-28
JP3248584B2 (ja) 2002-01-21
IL116512A0 (en) 1996-07-23
GB9524630D0 (en) 1996-01-31
WO1996020216A1 (en) 1996-07-04
CZ198497A3 (en) 1997-10-15
SK81097A3 (en) 1997-12-10
US6034056A (en) 2000-03-07
TR199501656A2 (tr) 1996-07-21
NO972930D0 (no) 1997-06-23
AU4269896A (en) 1996-07-19
PL320995A1 (en) 1997-11-24
AU705717B2 (en) 1999-05-27
BR9510284A (pt) 1998-01-06

Similar Documents

Publication Publication Date Title
MX9704767A (es) Inhibidores de la adhesion de fibronectina.
ATE165836T1 (de) Peptide als arzneimittel
NZ332778A (en) Cyclic peptides that are cell adhesion inhibiting compounds that inhibit the interaction of vascular cell adhesion molecule-1 and fibronectin with integrin very late antigen and mucosal addressin cell adhesion molecule-1
DE10075019I2 (de) Neue Proteine mit TNF-Hemmender Wirkung und ihre Herstellung.
DE3875538D1 (de) Aminoluciferine, verfahren zu deren herstellung und ihre verwendung.
Atlas The active site of porcine elastase
Witkop Chemical Cleavage of Proteins: Selective fragmentations and modifications reveal structure.
DE69009476D1 (de) Hemmung des reaktionswegs für die n-ende-regel in lebenden zellen.
Katsoyannis The synthesis of the insulin chains and their combination to biologically active material
DK109280A (da) Tripeptider og fremgangsmaade til fremstilling deraf
Franciskovich et al. A systematic evaluation of the inhibition of HIV-1 protease by its C-and N-terminal peptides
EP0421367B1 (en) Anticoagulant peptides
ATE140234T1 (de) Neue inhibitorische peptide
ATE245168T1 (de) Peptide, die anti-zellanhaftungsaktivität aufweisen
Köhl et al. Reevaluation of the C3a active site using short synthetic C3a analogues
DK0667781T3 (da) Peptidbaserede diagnostiske og terapeutiske midler til spondylarthropatier
US6159746A (en) Solid phase immunoassay to detect inhibitors of proteolytic enzymes
Moroder et al. Studies on cytochrome c. Part I. Synthesis of the protected hexadecapeptide (sequence 1–16) of Baker's Yeast iso‐1‐cytochrome c
WO1993000108A1 (en) Novel inhibitors of platelet aggregation
Ten Kortenaar et al. Semisynthesis of horse heart cytochrome c analogues from two or three fragments.
Wieland The history of peptide chemistry
Nozaki et al. Synthetic studies on troponin I active site. Preparation of a pentadecapeptide with inhibitory activity toward actomyosin adenosine triphosphatase
NO993684L (no) Peptider som omfatter et T-celle-epitop spesifikt til kollagen-II
ATE85077T1 (de) Enzym zur alpha-amidierung von c-termini und verfahren zu dessen herstellung.
ATE46173T1 (de) Pharmakologisch aktive peptide.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application